We summarized existing research on weight loss medications in rheumatic disease and their potential for improving quality of ...
Exposure to TNF inhibitors and IL-17 inhibitors is associated with a lower risk for osteoporosis among patients with ankylosing spondylitis.
Using routinely collected baseline data across 11 registries, prediction of remission showed limited discrimination and was best suited to ruling out remission. Performance was similar for a ...
MedPage Today on MSN
IBD drugs and heart attacks; AI finds occult pancreatic cancer; managing hemorrhoids
News and commentary from the world of gastroenterology and hepatology ...
Introduction: SAPHO syndrome is a rare autoimmune/autoinflammatory disorder with no approved therapies or standardized management guidelines. Biologic and targeted synthetic DMARDs (b/tsDMARDs) are ...
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape The rheumatoid arthritis ...
Today, AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating ...
Baseline osteoporosis and axial disease predicted higher odds of needing to switch therapies in pediatric chronic nonbacterial osteomyelitis.
Switching to guselkumab for psoriasis treatment was associated with the greatest rate of treatment persistence when compared with other therapies.
ANSWER: Denosumab (Prolia) is a treatment for osteoporosis that is normally given as an injection every six months. Among its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results